Experienced in Secondary Parkinsonism

Dr. Kore K. Liow

Hawaii Pacific Neuroscience LLC
Honolulu, HI
Experienced
in Secondary Parkinsonism
Specialties:Neurology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Kore Liow is a Neurologist in Honolulu, Hawaii. Dr. Liow and is rated as an Experienced provider by MediFind in the treatment of Secondary Parkinsonism. His top areas of expertise are Seizures, Epilepsy, Generalized Tonic-Clonic Seizure, and Memory Loss. Dr. Liow is currently accepting new patients.

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in KS
Languages Spoken
English
Mandarin
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  HMSA
  •  Humana

Locations

HAWAII PACIFIC NEUROSCIENCE LLC
2230 Liliha St, Honolulu, HI 96817
808-261-4476

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

CORE-VNS: Comprehensive Outcomes Registry in Subjects With Epilepsy Treated With Vagus Nerve Stimulation Therapy
CORE-VNS: Comprehensive Outcomes Registry in Subjects With Epilepsy Treated With Vagus Nerve Stimulation Therapy
Enrollment Status: Completed
Publish Date: November 22, 2024
Intervention Type: Device
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drug: TAK-994
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: July 19, 2024
Intervention Type: Drug
Study Drug: T3D-959
Study Phase: Phase 2
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drug: YKP3089
Study Phase: Phase 3
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
Enrollment Status: Terminated
Publish Date: December 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2023
Intervention Type: Drug, Combination product
Study Drugs: ND0612 Solution, Carbidopa, Levodopa
Study Phase: Phase 3
A 6-Month Multicenter, Open-Labelled Extension of the Clinical Trial NLS-1021 in Narcoleptic Patients With and Without Cataplexy
A 6-Month Multicenter, Open-Labelled Extension of the Clinical Trial NLS-1021 in Narcoleptic Patients With and Without Cataplexy
Enrollment Status: Completed
Publish Date: March 13, 2023
Intervention Type: Drug
Study Drug: Mazindol
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD) or Early Parkinson's Disease (PD)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD) or Early Parkinson's Disease (PD)
Enrollment Status: Completed
Publish Date: February 28, 2023
Intervention Type: Drug
Study Drug: Posiphen
Study Phase: Phase 1/Phase 2
A Four-week, Double-blind, Placebo-controlled, Randomized, Multicenter, Parallel-group Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in Adults for the Treatment of Narcolepsy
A Four-week, Double-blind, Placebo-controlled, Randomized, Multicenter, Parallel-group Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in Adults for the Treatment of Narcolepsy
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Drug
Study Drug: Mazindol
Study Phase: Phase 2
An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Buccal Film (DBF) in Pediatric, Adolescent and Adult Subjects With Epilepsy
An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Buccal Film (DBF) in Pediatric, Adolescent and Adult Subjects With Epilepsy
Enrollment Status: Completed
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern
A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern
Enrollment Status: Completed
Publish Date: February 03, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 12 Less Clinical Trials

43 Total Publications

Progression of Dopaminergic Therapy Changes in Parkinson's Disease in Asian and Native Hawaiian and Pacific Islander Populations.
Progression of Dopaminergic Therapy Changes in Parkinson's Disease in Asian and Native Hawaiian and Pacific Islander Populations.
Journal: Movement disorders clinical practice
Published: July 05, 2024
Similar Doctors
Expertise in
5
conditions
Dr. Kevin G. Kimata
Neurology
Expertise in
5
conditions
Dr. Kevin G. Kimata
Neurology

Neurology Associates Inc

321 N Kuakini St, Suite 810, 
Honolulu, HI 
 (0.6 mi)
808-523-5885
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kevin Kimata is a Neurologist in Honolulu, Hawaii. Dr. Kimata and is rated as an Advanced provider by MediFind in the treatment of Secondary Parkinsonism. His top areas of expertise are Migraine with Brainstem Aura, Alcoholic Neuropathy, Secondary Parkinsonism, and Gumma. Dr. Kimata is currently accepting new patients.

Expertise in
32
conditions
Dr. Brandon K. Hirota
Neurology
Expertise in
32
conditions
Dr. Brandon K. Hirota
Neurology

Straub Clinic And Hospital

888 S King St, 
Honolulu, HI 
 (1.8 mi)
808-522-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brandon Hirota is a Neurologist in Honolulu, Hawaii. Dr. Hirota and is rated as a Distinguished provider by MediFind in the treatment of Secondary Parkinsonism. His top areas of expertise are Peripheral Neuropathy, Myotonic Dystrophy Type 2, Myotonic Dystrophy, and Cerebellar Degeneration. Dr. Hirota is currently accepting new patients.

Expertise in
1
conditions
Dr. Leah L. Ridge
Neurology
Expertise in
1
conditions
Dr. Leah L. Ridge
Neurology
1010 S King St, Suite 106, 
Honolulu, HI 
 (1.9 mi)
808-486-7199
Languages Spoken:
English, Ilocano, Italian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Leah Ridge is a Neurologist in Honolulu, Hawaii. Dr. Ridge and is rated as an Experienced provider by MediFind in the treatment of Secondary Parkinsonism. Her top areas of expertise are Migraine, Secondary Parkinsonism, Restless Legs Syndrome, and Stroke. Dr. Ridge is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile